Ken Griffin Travere Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 61,000 shares of TVTX stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,000

Previous 30,500 100.0%

Holding current value

$1.06 Million

Previous $250,000 241.2%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $1.06 Million - $2.05 Million	134,780 Added 21.05%	775,089 $10.8 Million
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $2.55 Million - $4.02 Million	485,681 Added 314.1%	640,309 $5.26 Million
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $604,354 - $826,569	-84,172 Reduced 35.25%	154,628 $1.19 Million
Q4 2023 Feb 14, 2024	SELL	$5.44 - $9.5 $1.65 Million - $2.89 Million	-303,762 Reduced 55.99%	238,800 $2.15 Million
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $3.89 Million - $8.78 Million	509,037 Added 1518.38%	542,562 $4.85 Million
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $13.4 Million - $19.8 Million	-876,474 Reduced 96.32%	33,525 $514,000
Q1 2023 May 15, 2023	SELL	$17.82 - $22.89 $785,772 - $1.01 Million	-44,095 Reduced 4.62%	909,999 $20.5 Million
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $2.69 Million - $3.81 Million	-145,596 Reduced 13.24%	954,094 $20.1 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $4.73 Million - $5.91 Million	-206,346 Reduced 15.8%	1,099,690 $27.1 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $2.78 Million - $3.98 Million	-132,742 Reduced 9.23%	1,306,036 $31.6 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $14.5 Million - $18.7 Million	612,402 Added 74.11%	1,438,778 $37.1 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $584,306 - $748,267	24,006 Added 2.99%	826,376 $25.7 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $10.1 Million - $19.5 Million	777,966 Added 3187.86%	802,370 $19.5 Million
Q2 2021 Aug 16, 2021	BUY	$14.11 - $26.4 $73,386 - $137,306	5,201 Added 27.08%	24,404 $356,000
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $22.1 Million - $30 Million	-945,325 Reduced 98.01%	19,203 $480,000
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $18.5 Million - $26.9 Million	964,528 New	964,528 $26.3 Million

Others Institutions Holding TVTX

# of Institutions

192

Shares Held

84.5M

Call Options Held

776K

Put Options Held

900K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account